

Freedom of Information Request – 4240 v2

Under the Freedom of Information Act 2000, I would be grateful if you could provide answers to the following questions

- 1. Does your Trust routinely provide bisphosphonates to postmenopausal women with primary breast cancer to reduce the risk of their cancer spreading to other parts of the body?**

Please see below our Breast Services response below in accordance with NICE guidance.

- 2. If your Trust does routinely provide bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body, but is not providing them for all postmenopausal women, how is eligibility defined? For example, women at increased risk of recurrence.**

Eligibility is defined with the evidence of a DEXA Scan

- 3. If your Trust does routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, which bisphosphonates do you prescribe? For example, zoledronic acid, ibandronic acid, sodium clodronate.**

Zoledronic Acid

- 4. If your Trust does not routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, what are your reasons for not doing so?**

Please see below our Breast Services response below in accordance with NICE guidance.

Baseline assessment tool for early and locally advanced breast cancer: diagnosis and management (NICE clinical guideline NG101)

1.9 Bisphosphonate therapy			
Adjuvant bisphosphonate therapy			
Offer bisphosphonates (zoledronic acid or sodium clodronate) as adjuvant therapy to postmenopausal women with node-positive invasive breast cancer.	1.9.1	Partial	Offer to those with evidence of osteopaenia
Consider bisphosphonates (zoledronic acid or sodium clodronate) as adjuvant therapy for postmenopausal women with node-negative invasive breast cancer and a high risk of recurrence.	1.9.2	Partial	
Discuss the benefits and risks of bisphosphonate treatment with women, particularly the risk of osteonecrosis of the jaw, atypical femoral fractures and osteonecrosis of the external auditory canal. Follow the Medicines and Healthcare products Regulatory Agency/Commission on Human Medicines (MHRA/CHM) advice on bisphosphonates.	1.9.3	Yes	